Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 1001-1003

  Costero, Olga ^a   Picazo, Mari Luz ^a   Zamora, Pilar ^a   Romero, Sara ^a   Martinez Ara, Jorge ^a   Selgas, Rafael ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Focal segmental glomerulosclerosis; Renal cell carcinoma; Sunitinib; Thrombotic microangiopathy; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; AMLODIPINE; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

AGED; ARTICLE; BLOOD SMEAR; CASE REPORT; DRUG INHIBITION; FEMALE; FOCAL GLOMERULOSCLEROSIS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, RENAL CELL; ENALAPRIL; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INDOLES; KIDNEY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; PROTEIN-TYROSINE KINASES; PYRROLES; THROMBOTIC MICROANGIOPATHIES;

EID: 77649222696     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp666     Document Type: Article

References (13)

1. Obhrai JS, Patel VT, Humphreys BD. Progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int 2008; 74: 685-686
2. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100: 282-284
3. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
4. Frangie C, Lefaucheur C, Medioni J, et al. Renal thrombotic micro-angiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8: 177-178
5. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191
6. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799
7. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49: e23-e29
8. Stokes MB, Erazo MC, Agati DD. Glomerular disease related to anti-VEGF therapy. Kidney Int 2008; 74: 1487-1491
9. Kapiteijn E, Brand A, Kroep J. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalo-pathy syndrome. Ann Oncol 2007; 18: 1745-1747
10. Bollée G, Patey N, Cazajous G, et al. Trombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009; 24: 682-685
11. Winn S, Ellis S, Savage P, et al. Biopsy proven acute intrestitial nephritis associated with the tyrosyne kinase inhibitor sunitinib: a class effect?. Nephrol Dial Transplant 2009; 24: 673-675
12. Shiiki H, Dohi K, Hanatani M, et al. Focal and segmental glomerulo-sclerosis in preeclamptic patients with nephrotic syndrome. Am J Ne-phrol 1990; 10: 205-212
13. Greenberg A, Bastacky SI, Iqbal A, et al. Focal segmental glomerulo-sclerosis associated with nephrotic syndrome in cholesterol ather-oembolism: clinicopathological correlations. Am J Kidney Dis 1997; 29: 334-344